Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

INCLUDE-CKD: INCLUsive Digital carE for Chronic Kidney Disease (INCLUDE-CKD)

21. Mai 2026 aktualisiert von: Portsmouth Hospitals NHS Trust
This study will provide valuable insights into the demographics of MyRenalCare users, their digital adherence, and the overall impact of the app on health outcomes, healthcare costs, and environmental sustainability.

Studienübersicht

Status

Noch keine Rekrutierung

Intervention / Behandlung

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

1000

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

  • Retrospective: ~450-500 existing users + matched controls(24 months data).
  • Comparison with entire WKC CKD population
  • Prospective: ~500-550 new users + matched controls (6 months).
  • Exploratory: ~500 dialysis or pre transplant MyRenalCare users (no matched controls).
  • Qualitative: 15-25 patients + 10-15 staff.

Beschreibung

Inclusion Criteria:

5.1.1 Inclusion criteria - MyRenalCare users (retrospective and prospective cohorts)

Adults will be eligible for inclusion in the MyRenalCare cohorts if they meet all of the following:

  1. Aged 18 years or over.
  2. Under the care of the Wessex Kidney Centre
  3. Registered with, or offered and subsequently enrolled onto, the MyRenalCare platform during the defined retrospective or prospective periods.
  4. Able to understand study information and, where applicable, provide informed consent for use of their data for research purposes.

Specific CKD stage definitions and thresholds (e.g. based on eGFR, albuminuria or uPCR) will be documented in the study manual to ensure consistent application.

5.1.2 Inclusion criteria - matched usual care controls

Adults will be eligible for inclusion in the matched control cohorts if they meet all of the following:

  1. Aged 18 years or over.
  2. Under the care of the Wessex Kidney Centre for chronic kidney disease.
  3. Not registered with or using MyRenalCare at any point during the relevant observation period.
  4. Have sufficient clinical and administrative data available in the renal electronic patient record to enable matching and outcome assessment.

Controls will be identified retrospectively from the renal electronic patient record and matched to MyRenalCare users using a predefined matching strategy.

5.1.3 Inclusion criteria - qualitative interview participants (patients and staff)

Patients will be eligible to take part in the qualitative interview component if they meet all of the following:

  1. Aged 18 years or over.
  2. Currently using, or recently offered, the MyRenalCare platform as part of their CKD care at the Wessex Kidney Centre.
  3. Able to understand spoken and written English to the extent required for participation in an interview.
  4. Able and willing to provide written informed consent for participation in a recorded interview.
  5. Belong to a demographic or clinical subgroup of interest for the study (e.g. varying age, ethnicity, CKD stage, or digital engagement level), as part of purposive sampling to support diversity and equity analysis.

Clinical staff will be eligible if they meet all of the following:

  1. Employed by PHU or working in direct partnership with the Wessex Kidney Centre.
  2. Directly involved in the care of patients with chronic kidney disease and/or in the implementation or support of MyRenalCare.
  3. Able and willing to provide informed consent for a recorded interview.
  4. Able to reflect on experiences and observations relevant to the delivery, uptake, or equity implications of digital health in CKD.

Exclusion Criteria:

  1. Patients with acute kidney injury without established chronic kidney disease.
  2. Patients with a very limited life expectancy where participation in routine digital monitoring is not appropriate, as judged by the clinical team.
  3. Patients who have previously indicated that they do not wish their routinely collected clinical data to be used for research where such opt-out applies to this study.
  4. Patients who are unable to be identified reliably in the available data sources (for example, inconsistent or missing key identifiers).
  5. Any other situation where, in the opinion of the responsible clinician, participation in the study processes (including data use) would be inappropriate or unduly burdensome.
  6. Clinical staff who are not directly involved in the care of patients with chronic kidney disease or in the implementation of the MyRenalCare platform.
  7. Staff members currently on extended leave or unable to participate during the data collection period.
  8. Individuals who do not wish to have their views included in recorded interview transcripts or are unable to provide informed consent for participation.
  9. Any situation where, in the opinion of the study team or the individual's manager, participation would be inappropriate or burdensome due to role, availability, or conflict of interest.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Existing MyRenalCare users (retrospective cohort)
Adults who were already registered and actively using MyRenalCare at the start of the retrospective observation period. Data will be collected retrospectively from their routine use of the platform.
Study is non-interventional.
Andere Namen:
  • non-interventional
New MyRenalCare users (prospective cohort)
Adults who are newly offered and enroll onto MyRenalCare during the defined recruitment window. Participants will use the platform as part of routine care, and their engagement will be prospectively monitored.
Study is non-interventional.
Andere Namen:
  • non-interventional
Matched usual care controls
Adults with CKD receiving standard care at the Wessex Kidney Centre who are not enrolled onto MyRenalCare. These participants receive usual clinical care without access to the MyRenalCare platform.
Study is non-interventional.
Andere Namen:
  • non-interventional
Patients and staff participating in qualitative interviews (qualitative cohort)
A subset of MyRenalCare users (both retrospective and prospective) and clinical staff involved in their care who are invited to take part in interviews about their experiences with MyRenalCare.
Study is non-interventional.
Andere Namen:
  • non-interventional

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Primary
Zeitfenster: 12 months
Outcome measure 1: Number and proportion of MyRenalCare users by age, sex, ethnicity and Index of Multiple Deprivation quintile, compared with the CKD population under Wessex Kidney Centre care. Prevalence ratios will also be calculated.
12 months
Primary
Zeitfenster: 12-months

Outcome measure 2:

Composite digital adherence score (0-100) for MyRenalCare users, combining log-in frequency, completeness of blood pressure and symptom entries, use of secure messaging and duration of sustained use. Analyses stratified by age, sex, ethnicity and deprivation.

12-months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Secondary
Zeitfenster: 12-months
Outcome measure1: Number of unplanned and planned hospital admissions for MyRenalCare users compared with matched usual-care controls.
12-months
Secondary
Zeitfenster: 12-months
Outcome measure 2: Number of outpatient visits (renal and non-renal) for MyRenalCare users compared with matched usual-care controls.
12-months
Secondary
Zeitfenster: 12-months
Outcome measure 3: CKD progression, measured by change in eGFR, movement between CKD stages, and initiation of kidney replacement therapy for MyRenalCare users versus matched controls.
12-months
Secondary
Zeitfenster: 12-months
Outcome measure 4: NHS healthcare costs per patient-year for MyRenalCare users compared with matched usual-care controls, including inpatient, outpatient, emergency and relevant community or virtual care contacts.
12-months
Secondary
Zeitfenster: 12-months
Outcome measure 5: Estimated patient travel-related CO₂ emissions for renal care appointments for MyRenalCare users versus matched usual-care controls, based on travel distance and mode.
12-months
Secondary
Zeitfenster: 12-months
Outcome measure 6: Themes from qualitative interviews with patients and staff on MyRenalCare usability, support needs, barriers and facilitators to digital engagement.
12-months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

19. Mai 2026

Primärer Abschluss (Geschätzt)

31. Dezember 2026

Studienabschluss (Geschätzt)

31. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

7. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Mai 2026

Zuerst gepostet (Tatsächlich)

29. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Chronisches Nierenleiden

Klinische Studien zur Non-Interventional Study

Abonnieren